Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment
NCT ID: NCT04834570
Last Updated: 2021-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
105 participants
OBSERVATIONAL
2020-10-05
2022-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer
NCT00226928
Understanding Shared Psychobiological Pathways
NCT00245219
Diagnostics and Therapy of Disease-Related Quality of Life of Patients With Breast Cancer
NCT00145743
Psychosocial Support in Treating Women With Recurrent Breast Cancer or Stage I, Stage II, or Stage IV Breast Cancer
NCT00416780
The Effect of Appropriate Family Companionship on the Physical and Mental Health of Patients With Advanced Breast Cancer
NCT06385665
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast Cancer Survivors
Women who have survived breast cancer for at least 1 year (12 months) and 2 years (24 months) after the end of primary treatment
Quality of life in Breast Cancer Survivors
The patient will receive the following questionnaires to be completed :
* EORTC QLQ-C30
* EORTC QLQ - BR-23
* FACT-B
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quality of life in Breast Cancer Survivors
The patient will receive the following questionnaires to be completed :
* EORTC QLQ-C30
* EORTC QLQ - BR-23
* FACT-B
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult women (age ≥ 20 years old and less than 60 years old)
* Patient who has been treated by surgery, with or without adjuvant chemotherapy
* Clinical Stages I, II and III
* Patients considered cured, without history of recurrences
* Patients who completed treatment within a minimum of 1 year and are currently being undergoing outpatient follow-up
Exclusion Criteria
* Bilateral breast cancer
* Patient unable to fill out the QoL questionnaire
* Patient with disease recurrence
* Patient with metastatic breast cancer
20 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Brasileiro de Controle do Cancer
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thiago Vidal Brito
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IBCC Oncologia
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
32155120.7.0000.0072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.